Skip to content
Action Kidney Cancer Logo Action Kidney Cancer Logo
  • Home
  • About us
  • Contact us
  • Help & support
  • Kidney cancer
  • Research
  • Get involved
  • Downloads
  • Home
  • About us
  • Contact us
  • Help & support
  • Kidney cancer
  • Research
  • Get involved
  • Downloads
Helpline
0800 121 8721
Email us
Donate

ESMO Virtual 2020: Quality of life impact of immune checkpoint inhibitors

Home/Uncategorized/ESMO Virtual 2020: Quality of life impact of immune checkpoint inhibitors

ESMO Virtual 2020: Quality of life impact of immune checkpoint inhibitors

30 Sep 2020

Tags
checkpoint inhibitors immunotherapy quality of life renal cell carcinoma
  • View Larger Image
Listen to this News
Print this News

Share this Page:

FacebookTwitterLinkedInWhatsAppTumblrPinterestVkXingEmail

Immune checkpoint inhibitors have changed the way renal cell carcinoma (RCC) is treated and may improve quality of life. During a presentation at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 last week the results from a large analysis of the use of immune checkpoint inhibitors in different cancers was presented. The study showed that quality of life is improved with only certain drugs and only in certain types of cancer.

The researchers looked at 26 studies including 3,588 patients that investigated the effect of the immune checkpoint inhibitors nivolumab, pembrolizumab, ipilimumab, atezolizumab, durvalumab, and avelumab on quality of life. The types of cancer that were looked at were melanoma, non-small cell lung cancer (NSCLC), urothelial cancer, RCC, liver carcinoma, head and neck cancer, Merkel cell carcinoma, bladder cancer, and Hodgkin lymphoma.

They looked at change in quality of life in patients treated with these drug from before treatment to about 12-24 weeks later. There was no change in quality of life overall with the use of checkpoint inhibitors.

“Immune checkpoint inhibitors are generally well tolerated,” said Dr. Gonzalez, the chief investigator. “Overall, there really are no changes [in quality of life] over time. However, there are subgroups for which there are improvements, like patients receiving durvalumab, and there are subgroups in which there is deterioration [in quality of life], such as patients being treated with ipilimumab or for melanoma. Overall, there is better quality of life at follow-up for immune checkpoint inhibitor recipients than patients in comparator groups. We see greater benefits among patients treated with nivolumab or pembrolizumab and a greater benefit among head & neck cancer and renal cell cancer patients. We are hopeful that these data may help clinicians summarise the impact on quality of life of checkpoint inhibitors.”

Read more in Practice Update here

Listen to this News
Print this News

Share this Page:

FacebookTwitterLinkedInWhatsAppTumblrPinterestVkXingEmail

Kidney cancer news

26 May 2023

Cancer Charity Forum

Read More

26 May 2023

Coping with the emotional challenges of cancer

Read More

25 May 2023

Bisphosphonates for the treatment of kidney cancer bone metastases

Read More

23 May 2023

Finding kidney cancer

Read More

18 May 2023

Cabozantinib plus atezolizumab in non-clear cell kidney cancer

Read More

15 May 2023

Triple combination improves survival in patients with advanced kidney cancer

Read More

12 May 2023

NHS cancer backlog reduced

Read More

12 May 2023

Quitting smoking reduces risk for kidney cancer progression

Read More

9 May 2023

New NHS GP access recovery plan

Read More

4 May 2023

Factors influencing kidney cancer outcomes with immunotherapy

Read More

20 Apr 2023

CAR T-cell therapy shows promise for the treatment of advanced kidney cancer

Read More

14 Apr 2023

Brain metastases from kidney cancer treated with first-line therapies

Read More

Most used tags

renal cell carcinoma immunotherapy combination therapy checkpoint inhibitors Cancer nivolumab TKIs overall survival Opdivo sunitinib Sutent cabozantinib progression-free survival biomarkers NHS England Cabometyx ipilimumab COVID-19 pembrolizumab cancer survival axitinib VEGF inhibitors non-clear cell kidney cancer Inlyta coronavirus Yervoy risk factors Keytruda metastases adjuvant therapy biological markers papillary RCC targeted therapy everolimus Afinitor cancer outcomes ASCO first-line treatment NICE partial nephrectomy

Archives

  • 2023: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
  • 2022: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
  • 2021: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
  • 2020: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
  • 2019: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
  • 2018: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
  • 2017: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
  • 2016: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
  • About kidney cancer
  • Kidney cancer news
  • Kidney cancer treatments
  • Newsletter
  • Glossary
  • Useful links

Address

Action Kidney Cancer

11th Floor
3 Piccadilly Place
Manchester M1 3BN

Helpline

0800 121 8721
Email Us

About Action Kidney Cancer

We are the UK’s largest and most active patient-led kidney cancer charity. Whether you are a patient, survivor or someone you know has been diagnosed with kidney cancer, you have come to the right place to find support and information, and to be part of a caring and knowledgeable community of people: We are here to help you.
Registered charity in England, Wales (1164238), and Scotland (SC051330).
© Copyright Action Kidney Cancer 2021

Links

Home

About us

Donate

Contact us

Our partners

Branding by Kingswood Marketing

Policies

Website Policies

Complaints Policy

Equal Opportunities Policy

Information Governance Policy

Social Media Policy

Follow

Web Design by Douglass Digital

Helpline: 0800 121 8721

support@actionkidneycancer.org

Go to Top